Abstract: The current invention is directed to the therapeutic use of a composition comprising a therapeutically effective amount of a Urolithin or a precursor thereof, preferably suitable for use in reducing the risk of the recurrence of cancer or tumor formation in a patient in need thereof in the remission phase of a preceding cancer therapy in said patient.

Abstract: Use of a urolithin for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs), wherein the stem cell function is increased for at least 40 weeks.

Abstract: Use of a composition comprising a combination of a urolithin, a NAD precursor, preferably Nicotinamide Riboside and Vitamin B12 for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs).

Abstract: Use of a composition comprising a combination of a NAD+ precursor, preferably Nicotinamide Riboside and Vitamin B12 for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs).

Abstract: Use of a urolithin for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs).

Abstract: An agent for use in reducing T cell exhaustion and/or increasing T cell function, and/or boosting immunity, wherein the agent is selected from the group consisting of nicotinamide riboside, vitamin B12, a urolithin, manganese, serine, glycine, arginine, asparagine, and a combination of two or more thereof.

Abstract: The present invention relates to a specific marker for stem cells having long-term multi-lineage blood reconstitution capability and uses thereof for the preparation of cell composition in view of hematopoietic stem cell medicine and in particular regenerative therapies and bone marrow transplantation. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of decreased blood cell levels and the associated risk of infection.